Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.

doi:10.1073/pnas.2402913121

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.

Proceedings of the National Academy of Sciences of the United States of America - 3 Sept 2024

Fernández-García Fernando, Fernández-Rodríguez Ana, Fustero-Torre Coral, Piñeiro-Yáñez Elena, Wang Haiyun, Lechuga Carmen G, Callejas Sergio, Álvarez Rebeca, López-García Alejandra, Esteban-Burgos Laura, Salmón Marina, San Román Marta, Guerra Carmen, Ambrogio Chiara, Drosten Matthias, Santamaría David, Al-Shahrour Fátima, Dopazo Ana, Barbacid Mariano, Musteanu Monica

Abstract excerpt

Lung cancer is the leading cause of cancer mortality worldwide. KRAS oncogenes are responsible for at least a quarter of lung adenocarcinomas, the main subtype of lung cancer. After four decades of intense research, selective inhibitors of KRAS oncoproteins are finally reaching the clinic. Yet, their effect on overall survival is limited due to the rapid appearance of drug resistance, a likely consequence of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to AMP-Activated Protein Kinases

Share to Immune Checkpoint Inhibitors

Share to Interferon Type I

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 39186651
DOI: 10.1073/pnas.2402913121
PMCID: PMC11388366

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.PMID 39186651Read ↗

Low STING expression in a transplantable Kras G12D /P53 ko lung cancer model contributes to SiglecF + neutrophil and CD103 + Treg accumulation in tumorsSemantic proximity Read ↗

Therapeutic KRAS G12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancersSemantic proximity Read ↗

Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.Semantic proximity Read ↗

Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer.Semantic proximity Read ↗

Unveiling the role of KRAS in tumor immune microenvironment.Semantic proximity Read ↗

If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer.Semantic proximity Read ↗

The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog-mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis.Semantic proximity Read ↗

Pulmonary Inflammation and KRAS Mutation in Lung Cancer.Semantic proximity Read ↗

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and RestrictionsSemantic proximity Read ↗

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

Pharmacological rescue of tumor intrinsic STING expression and immune response in LKB1-mutant lung cancer via the IAP-JAK regulatory axisSemantic proximity Read ↗

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.